Results 191 to 200 of about 400,251 (340)

D‐glucuronyl C5‐Epimerase Binds to EGFR to Suppress Kidney Fibrosis

Advanced Science, EarlyView.
Glucuronyl C5‐epimerase (Hsepi, gene name Glce) is a key enzyme catalyzing heparan sulfate (HS) chain biosynthesis in HS proteoglycans, which are ubiquitously expressed on cell membranes. In normal renal tubular cells, Glce binds to the intracellular domains of EGFR, maintaining stable and orderly EGFR phosphorylation.
Xiaoqi Jing, Jun Wu, Jingru Ning, Xiaoyu Ding, Zhenyun Du, Xiaojiang Wang, Lulin Huang, Ran Wang, Changlin Mei, Kan Ding   +9 more
wiley   +1 more source

Will mTOR inhibitors make it as cancer drugs? [PDF]

, 2003
Charles L. Sawyers
openalex   +1 more source

Rictor Ameliorates Acute Antibody‐Mediated Rejection Following Kidney Transplantation by Suppressing Macrophage M1 Polarization Through p65‐NLRP3 Axis

Advanced Science, EarlyView.
This study elucidates the critical role of Rictor in macrophage activation in acute antibody‐mediated rejection (ABMR). Rictor increases K48‐linked ubiquitination of p65 by upregulating E3 ubiquitin ligase SOCS1, inhibiting transcriptional levels of NLRP3 and inflammasome activation.
Bin Ni, Chengcheng Yang, Junqi Zhang, Zhou Hang, Ming Zheng, Dengyuan Feng, Qinghuan Shen, Jinxu Miao, Xulin Sun, Li Sun, Baixin Shen, Min Gu, Zijie Wang   +12 more
wiley   +1 more source

mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E [PDF]

, 2003
Diane C. Fingar, Celeste Richardson, Andrew R. Tee, Lynn Cheatham, Christina Tsou, John Blenis   +5 more
openalex   +1 more source

NIR Driven Pd/Cerium Oxide Nano‐Heterojunction for Enhanced Salvaging Sepsis Induced Acute Liver Injury via Reprogramming Redox Homeostasis in Synergy with Inducing Autophagy

Advanced Science, EarlyView.
In vivo SALI therapy is achieved by scavenging intracellular ROS levels, downregulating inflammatory factors expression levels, inducing macrophage M2 directional polarization, and activating Keap1/Nrf‐2/HO‐1 pathway to reprogram redox homeostasis, induce cellular autophagy, reduce systemic inflammation, and promote liver tissue repair. Abstract Sepsis
Tao Qin, Lian Qin, Yang Zhao, Yin Chen, Qianyue Liu, Xiaoguang Lin, Yongfeng Lan, Yaohui Huang, Yan Liu, Ke Zhang, Lifan Pan, Jiaxiao Li, Kunpeng Duan, Hao Liang, Mingjing Yin, Guiyang Fan, Lian Liu, Yu Deng, Lin Liao, Danke Su, Ming Gao, Junyu Lu   +21 more
wiley   +1 more source

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

, 2002
Frédéric Pène, Yann-Érick Claessens, O. Müller, F Viguié, Patrick Mayeux, François Dreyfus, Catherine Lacombe, Didier Bouscary   +7 more
openalex   +1 more source

FKBP12-Rapamycin-associated Protein or Mammalian Target of Rapamycin (FRAP/mTOR) Localization in the Endoplasmic Reticulum and the Golgi Apparatus [PDF]

, 2003
Ryan M. Drenan, Xiangyu Liu, Paula Bertram, Xiao-Feng Zheng   +3 more
openalex   +1 more source

Inhibition of UBE2C Promotes Parkin‐Mediated K63‐Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer

Advanced Science, EarlyView.
In the study, UBE2C was found to be significantly overexpressed in breast cancer and transcriptionally regulated by FOXM1. Inhibition of UBE2C suppressed proliferation, induced senescence, and sensitized breast cancer cells to doxorubicin. Mechanistically, UBE2C inhibition promoted Parkin‐mediated K63‐linked ubiquitination of TOP2A.
Yihui Yang, Wan Li, Hong Yang, Fang Xu, Sen Zhang, Wanxin Cao, Xiaoxue Li, Xu Zhang, Xiangyin Chi, Hongquan Wang, Guanhua Du, Yumin Wang, Jinhua Wang   +12 more
wiley   +1 more source

Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner [PDF]

, 2003
Jayanta Debnath, Stephanie Walker, Joan S. Brugge   +2 more
openalex   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

Advanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan, Kun Shao, Roopa Hebbandi Nanjundappa, Daniel‐Jiajun Yu, Marianne Stanford, Huile Gao, Channakeshava Sokke Umeshappa   +6 more
wiley   +1 more source